ERYTECH Sells U.S. Manufacturing Facility and Enters Long-Term Supply Agreement with Catalent Post author:Marianne Duparc Post published:April 25, 2022 Post category:Newsroom ERYTECH Pharma announced the sale of its U.S. manufacturing facility to Catalent, a leading contract development and manufacturing organization (CDMO) in advanced therapies. You Might Also Like ERYTECH Provides Business and Financial Update for the First Half of 2022 September 12, 2022 ERYTECH Provides Business Update and Reports Financial Results for the First Half of 2020 September 21, 2020 Erytech to Hold Q1 2016 Business Update Conference Call on May 11th, 2016 May 2, 2016
ERYTECH Provides Business Update and Reports Financial Results for the First Half of 2020 September 21, 2020